tetano
Editor, Senior Moderator
Sci Rep
. 2021 Mar 24;11(1):6811.
doi: 10.1038/s41598-021-85848-5.
Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients
Yang Li[SUP] #[/SUP][SUP] 1 [/SUP], Yongzhong Jiang[SUP] #[/SUP][SUP] 2 [/SUP], Yi Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Naizhe Li[SUP] 1 [/SUP], Qiangling Yin[SUP] 1 [/SUP], Linlin Liu[SUP] 2 [/SUP], Xin Lv[SUP] 3 [/SUP], Yan Liu[SUP] 4 [/SUP], Aqian Li[SUP] 1 [/SUP], Bin Fang[SUP] 2 [/SUP], Jiajia Li[SUP] 5 [/SUP], Hengping Ye[SUP] 6 [/SUP], Gang Yang[SUP] 7 [/SUP], Xiaoxian Cui[SUP] 8 [/SUP], Yang Liu[SUP] 1 [/SUP], Yuanyuan Qu[SUP] 1 [/SUP], Chuan Li[SUP] 1 [/SUP], Jiandong Li[SUP] 1 [/SUP], Dexin Li[SUP] 1 [/SUP], Zhongtao Gai[SUP] 3 [/SUP], Shiwen Wang[SUP] 9 10 [/SUP], Faxian Zhan[SUP] 11 [/SUP], Mifang Liang[SUP] 12 13 [/SUP]
Affiliations
Abstract
High rate of cardiovascular disease (CVD) has been reported among patients with coronavirus disease 2019 (COVID-19). Importantly, CVD, as one of the comorbidities, could also increase the risks of the severity of COVID-19. Here we identified phospholipase A2 group VII (PLA2G7), a well-studied CVD biomarker, as a hub gene in COVID-19 though an integrated hypothesis-free genomic analysis on nasal swabs (n = 486) from patients with COVID-19. PLA2G7 was further found to be predominantly expressed by proinflammatory macrophages in lungs emerging with progression of COVID-19. In the validation stage, RNA level of PLA2G7 was identified in nasal swabs from both COVID-19 and pneumonia patients, other than health individuals. The positive rate of PLA2G7 were correlated with not only viral loads but also severity of pneumonia in non-COVID-19 patients. Serum protein levels of PLA2G7 were found to be elevated and beyond the normal limit in COVID-19 patients, especially among those re-positive patients. We identified and validated PLA2G7, a biomarker for CVD, was abnormally enhanced in COVID-19 at both nucleotide and protein aspects. These findings provided indications into the prevalence of cardiovascular involvements seen in patients with COVID-19. PLA2G7 could be a potential prognostic and therapeutic target in COVID-19.
. 2021 Mar 24;11(1):6811.
doi: 10.1038/s41598-021-85848-5.
Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients
Yang Li[SUP] #[/SUP][SUP] 1 [/SUP], Yongzhong Jiang[SUP] #[/SUP][SUP] 2 [/SUP], Yi Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Naizhe Li[SUP] 1 [/SUP], Qiangling Yin[SUP] 1 [/SUP], Linlin Liu[SUP] 2 [/SUP], Xin Lv[SUP] 3 [/SUP], Yan Liu[SUP] 4 [/SUP], Aqian Li[SUP] 1 [/SUP], Bin Fang[SUP] 2 [/SUP], Jiajia Li[SUP] 5 [/SUP], Hengping Ye[SUP] 6 [/SUP], Gang Yang[SUP] 7 [/SUP], Xiaoxian Cui[SUP] 8 [/SUP], Yang Liu[SUP] 1 [/SUP], Yuanyuan Qu[SUP] 1 [/SUP], Chuan Li[SUP] 1 [/SUP], Jiandong Li[SUP] 1 [/SUP], Dexin Li[SUP] 1 [/SUP], Zhongtao Gai[SUP] 3 [/SUP], Shiwen Wang[SUP] 9 10 [/SUP], Faxian Zhan[SUP] 11 [/SUP], Mifang Liang[SUP] 12 13 [/SUP]
Affiliations
- PMID: 33762651
- DOI: 10.1038/s41598-021-85848-5
Abstract
High rate of cardiovascular disease (CVD) has been reported among patients with coronavirus disease 2019 (COVID-19). Importantly, CVD, as one of the comorbidities, could also increase the risks of the severity of COVID-19. Here we identified phospholipase A2 group VII (PLA2G7), a well-studied CVD biomarker, as a hub gene in COVID-19 though an integrated hypothesis-free genomic analysis on nasal swabs (n = 486) from patients with COVID-19. PLA2G7 was further found to be predominantly expressed by proinflammatory macrophages in lungs emerging with progression of COVID-19. In the validation stage, RNA level of PLA2G7 was identified in nasal swabs from both COVID-19 and pneumonia patients, other than health individuals. The positive rate of PLA2G7 were correlated with not only viral loads but also severity of pneumonia in non-COVID-19 patients. Serum protein levels of PLA2G7 were found to be elevated and beyond the normal limit in COVID-19 patients, especially among those re-positive patients. We identified and validated PLA2G7, a biomarker for CVD, was abnormally enhanced in COVID-19 at both nucleotide and protein aspects. These findings provided indications into the prevalence of cardiovascular involvements seen in patients with COVID-19. PLA2G7 could be a potential prognostic and therapeutic target in COVID-19.